Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase IV, Compassionate Use Program of Rasburicase for Treatment of Hyperuricemia in Children and Adolescence Patients With Tumor Lysis Syndrome

NCT00563771 is registered in ClinicalTrials.gov with Sanofi as lead sponsor.

NCT NCT00563771
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00563771 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase IV, Compassionate Use Program of Rasburicase for Treatment of Hyperuricemia in Children and Adolescence Patients With Tumor Lysis Syndrome
Lead sponsor
Sanofi
Phase
Phase 4
Overall status
Completed
Start date
March 31, 2003
Completion date
January 31, 2004
Enrollment
38 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hyperuricemia